Montreal, Monday, November 17, 2009- Serge Beausoleil, President of Viropro is proud to announce the appointment of Neville G. Chamberlain, A New York investment banker to its Board of Directors.

Neville G. Chamberlain is the Chief Executive Officer of ITS. Mr. Chamberlain is also the Founder and Chairman of the Board of International Acquisitions Services Inc. (“IAS”). Established in 1978, IAS has originated and placed transactions in excess of $3billion. These activities have included debt and equity placement, syndication and sales of a wide variety of commercial, retail and multifamily residential properties to domestic and offshore investment sources. IAS has also provided consulting services to several large domestic and offshore institutions.

Serge Beausoleil, President of Viropro comments: “Not only does Mr. Chamberlain bring with him very valuable financing expertise and an extremely impressive network of business partners but his appointment is also a testimony to the quality of our new business plan.”

Viropro Inc. conducts operations through its subsidiary Viropro International Inc., specializes in the transfer of its technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. The company’s principal objective is to provide manufacturing process technology transfers to pharmaceutical companies in emerging markets with unmet medical needs such as in South America, Asia and Africa. (www.viropro.com)

About Intas Biopharmaceuticals Limited:

Intas Biopharmaceuticals Limited is a fully integrated biopharmaceutical company based out of Ahmedabad, Gujarat, India. Since launch of biotechnology operations in May 2000, Research & Development (R&D) and Manufacturing of Biopharmaceutical products with a special focus on Oncology (Cancer) are the major thrust areas for the company. Intas Biopharmaceuticals is India's first and only biopharmaceutical company to receive European Union -Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility. (www.intasbiopharma.co.in)

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.

For more information on Viropro Inc., please visit our website onwww.viropro.com